161
Participants
Start Date
March 9, 2021
Primary Completion Date
January 30, 2025
Study Completion Date
January 30, 2025
Islatravir
ISL capsule taken by mouth.
Ulonivirine
Ulonivirine tablet taken by mouth.
BIC/FTC/TAF
BIC/FTC/TAF tablet taken by mouth.
Placebo to ISL
Placebo capsule matched to ISL taken by mouth.
Placebo to Ulonivirine
Placebo tablet matched to ulonivirine taken by mouth.
Placebo to BIC/FTC/TAF
Placebo tablet matched to BIC/FTC/TAF taken by mouth.
CHUV (centre hospitalier universitaire vaudois) ( Site 2605), Lausanne
Hopitaux Universitaires de Geneve HUG ( Site 2604), Geneva
Inselspital Universitaetsspital Bern ( Site 2603), Bern
Universitaetsspital Basel ( Site 2602), Basel
Universitaetsspital Zuerich ( Site 2601), Zuerich
Infectious Disease Specialists Of Atlanta PC ( Site 2704), Decatur
CHU de Toulouse - Hopital Purpan ( Site 2302), Toulouse
Chatham County Health Department ( Site 2707), Savannah
Triple O Research Institute, P.A. ( Site 2712), West Palm Beach
Hopital Gui de Chauliac. ( Site 2303), Montpellier
Midway Immunology and Research ( Site 2713), Ft. Pierce
CHU Hotel Dieu Nantes ( Site 2310), Nantes
Centre Hospitalier Regional du Orleans ( Site 2304), Orléans
Kansas City CARE Clinic ( Site 2703), Kansas City
Hopital Saint Louis ( Site 2308), Paris
Hopital Saint-Antoine ( Site 2307), Paris
Pitie Salpetriere University Hospital-Infectious Disease - Tropical Diseases ( Site 2306), Paris
DCOL Center for Clinical Research ( Site 2715), Longview
Texas Centers for Infectious Disease Associates P.A. ( Site 2709), Fort Worth
Saint Hope Foundation, Inc. ( Site 2716), Bellaire
Pueblo Family Physicians ( Site 2702), Phoenix
Men's Health Foundation ( Site 2710), Los Angeles
Hopital Avicenne ( Site 2305), Bobigny
Merck Sharp & Dohme LLC
INDUSTRY